Table 2.
Parameter | Case #1 | Case #2 | Case #3 |
---|---|---|---|
Romiplostim started (postdiagnosis) | 3 years (2015) | 2 years | 3 years |
Trial 1 | |||
Dose | 500 µg | 100 µg | 75 µg |
Frequency | Weekly | Weekly | Weekly |
Duration | 53 weeks | 38 weeks | 94 weeks |
Platelet range (× 109/L) | 31–722 | 35–221 | 42–595 |
Trial 2 | |||
Dose | 250 µg | 250 µg | 75 µg |
Frequency | Biweekly | Biweekly | Biweekly |
Duration | 11 weeks | 131 weeks | 20 weeks |
Platelet range (× 109/L) | 86–454 | 40–129 | 217–922 |
Trial 3 | |||
Dose | 500 µg | — | 75 µg |
Frequency | Weekly | — | Triweekly |
Duration | 42 weeks | — | 12 weeks |
Platelet range (× 109/L) | 31–1277 | — | 321–625 |
Current ITP status | Stable∗ | Partial remission | Complete remission |
∗On weekly dosing of romiplostim 230 µg.